{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:10:09Z","timestamp":1779088209539,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA248019"],"award-info":[{"award-number":["CA248019"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA266256"],"award-info":[{"award-number":["CA266256"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK130478"],"award-info":[{"award-number":["DK130478"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2023,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Drug repurposing, the strategy to identify new therapeutic use for clinically approved drugs has attracted much attention in recent years. This strategy offers various advantages over traditional approaches to develop new drugs, including shorter development timelines, low cost, and reduced risk of failure. In this issue of\n                    <jats:italic>EMBO Molecular Medicine<\/jats:italic>\n                    , Liu\n                    <jats:italic>et\u00a0al<\/jats:italic>\n                    show that inosine monophosphate dehydrogenase (IMPDH) inhibitors, the well\u2010known immunosuppressants have a potent therapeutic effect on the aggressive blood cancer, acute myeloid leukemia with MLL rearrangements. Intriguingly, the antileukemia effect of IMPDH inhibitors is mediated, at least in part through the overactivation of TLR signaling and Vcam1 upregulation. The robust antileukemia effect of IMPDH inhibitors, both\n                    <jats:italic>in\u00a0vitro<\/jats:italic>\n                    and\n                    <jats:italic>in\u00a0vivo<\/jats:italic>\n                    , together with their mechanistic findings provides a rational basis for repurposing IMPDH inhibitors for antileukemia therapy.\n                  <\/jats:p>","DOI":"10.15252\/emmm.202217042","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T07:41:10Z","timestamp":1669880470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Repurposing immunosuppressants for antileukemia therapy"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-2647","authenticated-orcid":false,"given":"Maiko","family":"Sezaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5457-5358","authenticated-orcid":false,"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"BFEMMM202217042_CR1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2016.10.003","volume":"30","author":"J Bajaj","year":"2016","unstructured":"Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, Oehler VG, Broome EH et\u00a0al (2016) CD98\u2010mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia. Cancer Cell 30: 792\u2013805","journal-title":"Cancer Cell"},{"key":"BFEMMM202217042_CR2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Wei AH (2020) How I treat acute myeloid leukemia in the era of new drugs. Blood 135: 85\u201396","journal-title":"Blood"},{"key":"BFEMMM202217042_CR3","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41467-019-12555-1","volume":"10","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Goyama S, Liu X, Tamura M, Asada S, Tanaka Y, Fukuyama T, Wunderlich M, O'Brien E, Mizukawa B et\u00a0al (2019) Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nat Commun 10: 4869","journal-title":"Nat Commun"},{"key":"BFEMMM202217042_CR4","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s41556-019-0363-9","volume":"21","author":"S Kofuji","year":"2019","unstructured":"Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren\u00a0M, Sakamoto N, Kitahara S et\u00a0al (2019) IMP dehydrogenase\u20102 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nat Cell Biol 21: 1003\u20131014","journal-title":"Nat Cell Biol"},{"key":"BFEMMM202217042_CR5","volume":"15","author":"X Liu","year":"2022","unstructured":"Liu X, Sato N, Yabushita T, Li J, Jia Y, Tamura M, Asada S, Fujino T, Fukushima T, Yonezawa T et\u00a0al (2022) IMPDH inhibition activates TLR\u2010VCAM1 pathway and suppresses the development of MLL\u2010fusion leukemia. EMBO Mol Med 15: e15631","journal-title":"EMBO Mol Med"},{"key":"BFEMMM202217042_CR6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091346","volume":"11","author":"R Naffouje","year":"2019","unstructured":"Naffouje R, Grover P, Yu H, Sendilnathan A, Wolfe K, Majd N, Smith EP, Takeuchi K, Senda T, Kofuji S et\u00a0al (2019) Anti\u2010tumor potential of IMP dehydrogenase inhibitors: a century\u2010long story. Cancers (Basel) 11: 1346","journal-title":"Cancers (Basel)"},{"key":"BFEMMM202217042_CR7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J et\u00a0al (2020) Monocytic subclones confer resistance to Venetoclax\u2010based therapy in patients with acute myeloid leukemia. Cancer Discov 10: 536\u2013551","journal-title":"Cancer Discov"},{"key":"BFEMMM202217042_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/835199","author":"AJ Valvezan","year":"2020","unstructured":"Valvezan AJ, McNamara MC, Miller SK, Torrence ME, Asara JM, Henske EP, Manning BD (2020) IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex. JCI Insight. https:\/\/doi.org\/10.1101\/835199","journal-title":"JCI Insight"},{"key":"BFEMMM202217042_CR9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020441","volume":"12","author":"AV Wojcicki","year":"2020","unstructured":"Wojcicki AV, Kadapakkam M, Frymoyer A, Lacayo N, Chae HD, Sakamoto KM (2020) Repurposing drugs for acute myeloid leukemia: a worthy cause or a futile pursuit? Cancers (Basel) 12: 441","journal-title":"Cancers (Basel)"},{"key":"BFEMMM202217042_CR10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s12185-015-1774-4","volume":"101","author":"A Yokoyama","year":"2015","unstructured":"Yokoyama A (2015) Molecular mechanisms of MLL\u2010associated leukemia. Int J Hematol 101: 352\u2013361","journal-title":"Int J Hematol"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202217042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.202217042","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.202217042\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.202217042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202217042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:48:32Z","timestamp":1779086912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.202217042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,11]]}},"alternative-id":["BFEMMM202217042"],"URL":"https:\/\/doi.org\/10.15252\/emmm.202217042","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"EMMM202217042"}}